Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
29.10
+1.91 (7.02%)
Feb 6, 2026, 4:00 PM EST - Market closed
Edgewise Therapeutics Employees
Edgewise Therapeutics had 136 employees as of September 30, 2025. The number of employees increased by 28 or 25.93% compared to the same quarter last year.
Employees
136
Change
28
Growth
25.93%
Revenue / Employee
n/a
Profits / Employee
-$1,156,184
Market Cap
3.08B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 136 | 28 | 25.93% |
| Jun 30, 2025 | 126 | 29 | 29.90% |
| Mar 31, 2025 | 117 | 25 | 27.17% |
| Dec 31, 2024 | 110 | 22 | 25.00% |
| Sep 30, 2024 | 108 | 28 | 35.00% |
| Jun 30, 2024 | 97 | 23 | 31.08% |
| Mar 31, 2024 | 92 | 25 | 37.31% |
| Dec 31, 2023 | 88 | 29 | 49.15% |
| Sep 30, 2023 | 80 | 30 | 60.00% |
| Jun 30, 2023 | 74 | 32 | 76.19% |
| Mar 31, 2023 | 67 | 29 | 76.32% |
| Dec 31, 2022 | 59 | 28 | 90.32% |
| Sep 30, 2022 | 50 | 20 | 66.67% |
| Jun 30, 2022 | 42 | 16 | 61.54% |
| Mar 31, 2022 | 38 | 16 | 72.73% |
| Dec 31, 2021 | 31 | 12 | 63.16% |
| Sep 30, 2021 | 30 | 11 | 57.89% |
| Jun 30, 2021 | 26 | - | - |
| Mar 31, 2021 | 22 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| Apellis Pharmaceuticals | 710 |
| Arcutis Biotherapeutics | 342 |
| Xenon Pharmaceuticals | 327 |
| Dyne Therapeutics | 240 |
| Vera Therapeutics | 224 |
| Catalyst Pharmaceuticals | 181 |
| Immunome | 168 |
EWTX News
- 2 days ago - Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 - PRNewsWire
- 5 days ago - Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PRNewsWire
- 25 days ago - Edgewise Therapeutics, Inc. (EWTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 25 days ago - Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 - PRNewsWire
- 4 weeks ago - Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - PRNewsWire
- 5 weeks ago - Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst - Seeking Alpha
- 6 weeks ago - Why Did Edgewise Therapeutics Jump 25%+ On Wednesday? - Forbes
- 6 weeks ago - Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - PRNewsWire